FRCA Notes


Ventilator-Associated Pneumonia

This is a frequent exam topic, and the relevant curriculum item is probably "the causes, preention and treatment of infections seen in... [the] critically ill".

VAP has appeared twice in the CRQ paper, in 2018 (pass rate 38.6%) and 2023 (30.3%); definition, preventative strategies against VAP and care bundles are all areas where marks have been lost en masse.

Resources


  • Ventilator-associated pneumonia (VAP) is defined as an infection of the pulmonary parenchyma occurring ≥48hrs after the initiation of invasive mechanical ventilation
    • It can be further sub-classified into early (onset ≤5 days) or late (onset >5 days) VAP

  • Microbial presence in the lower respiratory tract probably exists as a spectrum: airway colonisation → tracheobronchitis → pneumonia
  • VAP is associated with increased morbidity and mortality, although it is unclear whether VAP itself causes the poor outcomes

  • Prevalence of 15 - 20% amongst patients ventilated for ≥48hrs
    • Incidence of 13.6 per 1,000 ventilator days
    • Rates vary between regions (higher in Europe than North America), likely reflecting differences in definitions, screening and patient groups

  • Responsible for a large proportion of antibiotic use on ICU
  • Attributable mortality is debated, but estimated to be up to 13%
  • Associated with:
    • Up to 6 additional days of mechanical ventilation
    • Up to 10 additional days of ICU stay
    • An estimated cost of ∽£10,000 per patient in the UK

Risk factors

Patient factors Hospitalisation and ventilatory factors
Advanced age Admission with reduced conscious level
Male sex Burns or trauma
Smoking history Previous antibiotics, esp. if broad-spectrum
Immunosuppression Prolonged duration of I&V
Diabetes Supine position
Existing lung disease Re-intubation following unsuccessful extubation


  • The causative organisms tend to relate to the timing between onset of mechanical ventilation and start of VAP
  • It may be polymicrobial in nature

Early VAP

  • Methicillin-sensitive Staphylococcus aureus (MSSA)
  • Streptococcus pneumoniae
  • H. influenzae

Late VAP

  • Enteric, gram-negative bacilli
    • Pseudomonas aeruginosa
    • Klebsiella pneumoniae
    • E. coli
    • Acinetobacter
  • Drug-resistant organisms
    • MRSA
    • Multidrug-resistant (MDR) gram-negatives; ∽1/3 of Pseudomonas VAP is caused by MDR strains, with wide variation between countries

Risk factors for MDR organisms

  • Late onset (>5 days of invasive ventilation)
  • Previous exposure to broad-spectrum antibiotics

  • The presence of ETT or tracheostomy interferes with normal anatomy and physiology of the respiratory tract
    • Impaired cough
    • Impaired mucociliary function

  • Additionally, a reduced conscious level e.g. from sedation to facilitate I&V leads to:
    • Impaired secretion clearance
    • Pooling of secretions in the oropharynx, leading to (micro/macro) aspiration

  • There is a proliferation of normal oral flora, which form an antibiotic-resistant biofilm
  • Impaired innate and adaptive immunity from critical illness allows colonisation to progress to infection

  • There is no gold standard; diagnosis is based upon the triad of:
    1. Clinical suspicion
    2. Radiological evidence of infection
    3. Microbiological results

Definitions and scoring systems

  • ATS/IDSA definition
    • New lung infiltrate on CXR plus clinical evidence of infection, i.e. 2 of: fever, leucocytosis or purulent secretions
    • Growth of a causative organism on a respiratory sample confirms 'definite' VAP

  • Clinical Pulmonary Infection Score (CPIS)
    • Weighted score based on temperature, white cell count, tracheal secretions, CXR, oxygenation (P/F ratio) and culture of tracheal secretions
    • A score of >6 suggests a high probability of VAP, but CPIS has poor diagnostic accuracy

  • HELICS criteria
    • Used for surveillance across Europe
    • Requires radiological, systemic and respiratory criteria to all be met

  • CDC ventilator-associated event criteria
    • A surveillance tool using electronic health record data; sensitive but lacks specificity for clinically important VAP

Difficulties in diagnosis

  • Worsening oxygenation and new CXR infiltrates are common in critical illness, and often non-infective
    • Fluid overload
    • Atelectasis
    • Mucus plugging

  • The respiratory tract is not sterile; a positive culture may represent colonisation rather than infection
  • An organism isolated in the bloodstream may not be the same one causing the VAP

Lower respiratory tract sampling

  • Tracheal aspirate
Advantages Disadvantages
Cheap and easy to perform Proximal airway colonisation is common; may not represent true infection
Minimally invasive Risk of unnecessary antibiotic use, promoting MDR flora
Allows Gram stain and culture Novel tests (quantitative culture, PCR) not well validated on these samples

  • Bronchoalveolar lavage (BAL) via fibreoptic bronchoscope
Advantages Disadvantages
With quantitative culture, may better identify true VAP Invasive
May optimise antibiotic selection and reduce antibiotic exposure Requires more equipment and personnel
Poorly tolerated in severe hypoxaemia

  • Non-directed bronchial lavage (blind instillation and aspiration of saline) is a less invasive alternative
  • Invasive sampling has not been shown to improve patient-centred outcomes compared with minimally invasive techniques

Novel diagnostics

  • Multiplex PCR
    • Rapid detection of common VAP pathogens and resistance genes
    • Only 50 - 60% concordance with culture and cannot distinguish viable from non-viable organisms, so risks over-detection

  • Volatile organic compounds on HME filters
    • May detect VAP up to 3 days before clinical signs although currently a research tool only

  • Prevention strategies aim to reduce VAP incidence, but few have translated into a mortality benefit
Minimise time on ventilator Reduce risk of aspiration Optimise microbial ecology
Avoid (re-)intubation Elevate head of bed 30 - 45° Selective decontamination of the digestive tract (SDD)
Early extubation/early weaning protocol Subglottic suction/aspiration Oral hygiene
Daily sedation breaks and spontaneous breathing trials Maintain cuff pressure 20 - 30cmH2O Avoid routine ventilator circuit changes

Ventilator care bundle

  • The original ventilator bundle was comprised of:
    1. Head of bed elevation to 30°
    2. Daily sedation holds and spontaneous breathing trials
    3. Stress ulcer prophylaxis
    4. VTE prophylaxis
  • This has since been modified by many societies to include some of the measures in the table above
  • Bundles are associated with a reduced incidence of VAP, but the evidence comes from small before-and-after observational studies, at high risk of bias

Selective decontamination of the digestive tract

  • Non-absorbable antimicrobials applied to the oropharynx and GI tract ± a short course of IV antibiotics
  • The SuDDICU trial found no significant difference in mortality, but an accompanying meta-analysis suggested a high probability of reduced in-hospital mortality and VAP
    • The effect is greater when an IV antibiotic component is included
    • Patients at high risk of VAP, e.g. acute brain injury, may benefit most
  • Concern regarding promotion of MDR organisms so implementation requires local multidisciplinary agreement

Stress ulcer prophylaxis

  • PPIs raise gastric pH, which was thought to favour bacterial growth and increase VAP risk
  • Large RCTs comparing PPIs with placebo found no difference in infective complications
  • Current evidence suggests PPIs for stress ulcer prophylaxis are likely safe and not associated with increased VAP

Gastric residual volume (GRV) monitoring

  • Not monitoring GRV is non-inferior to routine monitoring with regards to VAP incidence
  • Routine GRV monitoring is not recommended for VAP prevention although it may still be used to guide feed tolerance

Prophylactic antibiotics

  • Inhaled amikacin, and short courses of IV antibiotics in patients with brain injury or post-cardiac arrest, have reduced VAP incidence in trials
  • No consistent mortality benefit has been shown thus this remains an area of ongoing research and is not routine practice

Empirical antibiotics

  • Choice is guided by risk factors for MDR organisms, the local antibiogram, clinical course and illness severity
  • Early-onset VAP with no MDR risk factors
    • Third-generation cephalosporin or co-amoxiclav

  • Late-onset VAP (>5 days) or MDR risk factors
    • Broad-spectrum anti-pseudomonal β-lactam, e.g. piperacillin-tazobactam, cefepime or meropenem
    • Add MRSA cover (vancomycin or linezolid) if at high risk

  • Narrow the spectrum according to microbiology results as soon as possible
  • Input from Microbiology regarding antimicrobial selection/organism resistance locally

Drawbacks of anti-pseudomonal agents

  • Meropenem: widespread use promotes carbapenemase-producing organisms
  • Piperacillin-tazobactam: may not adequately cover AmpC β-lactamase producers
  • Cefepime: associated with neurotoxicity (GABA receptor inhibition) and fewer delirium/coma-free days

Continuous infusion of β-lactams

  • β-lactams exhibit time-dependent killing, i.e. efficacy depends on the time the concentration remains above the MIC
  • The BLING III trial showed no significant difference in the primary analysis, but adjusted analysis and a subsequent meta-analysis favoured continuous infusion
  • Continuous infusion is recommended in VAP patients meeting criteria for sepsis or septic shock

Duration

  • Guidelines recommend 7 - 8 days in patients with a good clinical response
    • Shorter courses do not increase treatment failure and increase antibiotic-free days
    • Longer courses may be needed for immunodeficiency, cystic fibrosis, empyema, lung abscess, cavitation or necrotising pneumonia; decided with ID/Microbiology

  • The REGARD-VAP trial found individualised courses as short as 3 - 5 days were non-inferior to longer courses

Supportive management

  • Lung-protective ventilation, as these patients are at risk of ARDS
  • Corticosteroids: little evidence of benefit in VAP (unlike severe CAP)
  • Otherwise as for any other ICU patient


Effective Ongoing research Unclear or no benefit
Selective decontamination of the digestive tract Prophylactic antibiotics Gastric residual volume monitoring
Continuous β-lactam infusion Novel microbiological diagnostics Avoiding PPIs
Shorter treatment duration Care bundles
Narrowing the antibiotic spectrum Corticosteroids


  • A care bundle is:
  • A group of evidence-based interventions which, when delivered together, lead to a better clinical outcome than performing interventions individually


  • A recent review suggests the effect of ICU care bundles on patient outcomes may be inconclusive, except for the sepsis bundles (BMJ Open, 2023)

Examples

  • Ventilator care bundle
  • Central line insertion care bundle
    • Implementation of a CVC care bundle reduced catheter-related bloodstream infections to 66% of pre-bundle levels

  • Sepsis six care bundle
    • Implementation associated with a reduction in mortality of ∽6% over 2yrs

  • Delirium prevention care bundle